Endocrine resistance is a significant problem in breast cancer treatment. Thus identification and validation of novel resistance determinants is important to improve treatment efficacy and patient outcome. In our work, AGR2 expression was determined by qRT-PCR in Tru-Cut needle biopsies from tamoxifen-treated postmenopausal breast cancer patients. Our results showed inversed association of AGR2 mRNA levels with primary treatment response (P = 0.0011) and progression-free survival (P = 0.0366) in 61 ER-positive breast carcinomas. As shown by our experimental and clinical evaluations, elevated AGR2 expression predicts decreased efficacy of tamoxifen treatment. From this perspective, AGR2 is a potential predictive biomarker enabling selection of an optimal algorithm for adjuvant hormonal therapy in postmenopausal ER-positive breast cancer patients.

Regional Centre for Applied Molecular Oncology Masaryk Memorial Cancer Institute Zluty kopec 7 656 53 Brno Czech Republic

See more in PubMed

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. Ca: A Cancer Journal for Clinicians. 2005;55(2):74–108. PubMed

Katzenellenbogen BS, Frasor J. Therapeutic targeting in the estrogen receptor hormonal pathway. Seminars in Oncology. 2004;31(1):28–38. PubMed

Robertson JFR, Cannon PM, Nicholson RI, Blamey RW. Oestrogen and progesterone receptors as prognostic variables in hormonally treated breast cancer. International Journal of Biological Markers. 1996;11(1):29–35. PubMed

Hrstka R, Nenutil R, Fourtouna A, et al. The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers. Oncogene. 2010;29(34):4838–4847. PubMed

Innes HE, Liu D, Barraclough R, et al. Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients. British Journal of Cancer. 2006;94(7):1057–1065. PubMed PMC

Thompson DA, Weigel RJ. hAG-2, the human homologue of the Xenopus laevis cement gland gene XAG-2, is coexpressed with estrogen receptor in breast cancer cell lines. Biochemical and Biophysical Research Communications. 1998;251(1):111–116. PubMed

Pohler E, Craig AL, Cotton J, et al. The Barrett’s antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage. Molecular and Cellular Proteomics. 2004;3(6):534–547. PubMed

Liu D, Rudland PS, Sibson DR, Platt-Higgins A, Barraclough R. Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas. Cancer Research. 2005;65(9):3796–3805. PubMed

Wang Z, Hao Y, Lowe AW. The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation. Cancer Research. 2008;68(2):492–497. PubMed

Hengel SM, Murray E, Langdon S, et al. Data-independent proteomic screen identifies novel tamoxifen agonist that mediates drug resistance. Journal of Proteome Research. 2011;10(10):4567–4578. PubMed PMC

Abd El-Rehim DM, Ball G, Finder SE, et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. International Journal of Cancer. 2005;116(3):340–350. PubMed

McCarty KS, Jr., Miller LS, Cox EB, Konrath J, McCarty KS., Sr. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Archives of Pathology and Laboratory Medicine. 1985;109(8):716–721. PubMed

Hodges LC, Cook JD, Lobenhofer EK, et al. Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells. Molecular Cancer Research. 2003;1(4):300–311. PubMed

Arpino G, Green SJ, Allred DC, et al. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clinical Cancer Research. 2004;10(17):5670–5676. PubMed

Dong A, Gupta A, Pai RK, Tun M, Lowe AW. The human adenocarcinoma-associated gene, AGR2, induces expression of Amphiregulin through hippo pathway co-activator YAP1 activation. The Journal of Biological Chemistry. 2011;286(20):18301–18310. PubMed PMC

Hrstka R, Murray E, Brychtova V, Fabian P, Hupp TR, Vojtesek B. Identification of an AKT-dependent signalling pathway that mediates tamoxifen-dependent induction of the pro-metastatic protein anterior gradient-2. Cancer Letters. 2013;333:187–193. PubMed

Identification of AGR2 Gene-Specific Expression Patterns Associated with Epithelial-Mesenchymal Transition

AGR2 silencing contributes to metformin-dependent sensitization of colorectal cancer cells to chemotherapy

Suppression of AGR2 in a TGF-β-induced Smad regulatory pathway mediates epithelial-mesenchymal transition

AGR2 oncoprotein inhibits p38 MAPK and p53 activation through a DUSP10-mediated regulatory pathway

Anterior gradient protein 3 is associated with less aggressive tumors and better outcome of breast cancer patients